Amgen Poised to BEAT 2012 Guidance and 4 Stock Analyses Driving the Market

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

DTE Energy Co. (NYSE:DTE) reports a Q2 EPS of 86c, consensus 70c.

Crown Castle International Corp. (NYSE:CCI) is expected by Canaccord to benefit from strong secular tailwinds related to U.S. organic growth, as national carriers upgrade networks and accretive acquisitions. Shares have a Buy rating.

Don’t Miss: Chevron Earnings: CLIMBS Above Profit Estimate, Short on Revenue Mark.

Amgen Inc. (NASDAQ:AMGN) target has been raised by RBC Capital because the firm feels that the company is more attractive than its biotech peers, while it is poised to beat its guidance for 2012 and the consensus estimate for 2015. The firm does not see any major negative catalysts for the stock. The firm reiterates an Outperform rating on the stock.

Facebook, Inc. (NASDAQ:FB) estimates have been reduced by Barclays, and the firm predicts the rise in operating expenses to continue. Share have an Equal Weight rating.

Amarin Corporation plc (NASDAQ:AMRN): According to Jefferies, although approval of Amarin’s (NASDAQ:AMRN) Vascepa was expected, the label contains positive language that triglyceride benefits, not associated with LDL-C, increase. Jefferies thinks that the label may differentiate Vascepa from the current market leader, GlaxoSmithKline’s (NYSE:GSK) Lovaza. The firm maintains a Buy rating on the shares.

Don’t Miss: Apple Catches a Break — For Now.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business